Summary: Researchers have identified a biomarker in spinal fluid that can detect Parkinson’s disease in its early stages with over 90% accuracy. Using a patented immuno-infrared sensor (iRS) technology, they measured the misfolding of the alpha-synuclein (αSyn) protein, a key driver of the disease.
Early diagnosis is crucial, as clinical symptoms usually appear only after severe and irreversible brain damage. Beyond diagnosis, the platform could also accelerate the development and validation of new Parkinson’s therapies.
Key Facts:
- Early Detection: Misfolded alpha-synuclein (αSyn) in spinal fluid predicts Parkinson’s with over 90% sensitivity and specificity.
- Advanced Technology: The iRS platform detects protein misfolding, a method also validated in Alzheimer’s diagnostics.
- Therapeutic Potential: The biomarker may aid in developing and testing new Parkinson’s treatments by monitoring disease progression.
Source: RUB
Parkinson’s disease is a neurodegenerative disorder that is usually diagnosed in its late stage on the basis of clinical symptoms, mainly motor disorders.
By this point, however, the brain is already severely and irreparably damaged. Moreover, diagnosis is difficult and often incorrect because the disease takes many forms and symptoms overlap with other disorders.
Researchers from the PRODI Center for Protein Diagnostics at Ruhr University Bochum, Germany, and the biotech company betaSENSE have now discovered a biomarker in the spinal fluid that facilitates a reliable diagnosis at an early stage and can shed light on the progression of the disease and the effect of a therapy.
They report their findings in the journal EMBO Molecular Medicine on April 25, 2025.
Parkinson’s disease – an unstoppable condition
Parkinson’s disease is characterized by the loss of dopaminergic nerve cells in the brain, which usually leads to increasing motor impairments as the symptoms progress. Dopamine supplements can compensate for the loss and temporarily alleviate the symptoms.
The misfolding of the key protein alpha-synuclein (αSyn) from α-helical structures to β-sheet-rich structures plays a crucial role in the development of Parkinson’s disease.
“These misfoldings make the protein sticky, leading to the formation of larger complexes, so-called oligomers. The oligomers then produce long fibrillar filaments and cause the aggregation of these filaments into macroscopically large Lewy bodies in the brain,” explains Professor Klaus Gerwert, founding and managing director at PRODI and CEO of betaSENSE.
Advanced platform technology
In two independent clinical cohorts with a total of 134 participants, the Bochum-based researchers showed that, with a sensitivity and specificity of well over 90 percent, this misfolding of αSyn in body-fluids is a viable biomarker for the diagnosis of Parkinson’s disease.
The research was conducted using cerebrospinal fluid samples from patients at the Parkinson’s centers in Bochum (St. Josef Hospital, Professor Lars Tönges, Professor Ralf Gold) and Kassel (Paracelsus-Elena-Klinik, Dr. Sandrina Weber, Professor Brit Mollenhauer).
The measurements were carried out using the patented iRS (immuno-infrared sensor) technology from betaSENSE GmbH.
betaSENSE has already successfully implemented the iRS technology for diagnosing Alzheimer’s disease. In this case, it was shown that the misfolding of the biomarker Aβ can indicate the risk of Alzheimer’s dementia at a later stage with high accuracy up to 17 years before clinical diagnosis.
“We have now transferred this approach to Parkinson’s for the misfolding of αSyn,” stresses Klaus Gerwert.
Development of Parkinson’s drugs
In addition to diagnostic applications, the technology can also help to develop new active substances and prove their efficacy in clinical trials.
About this Parkinson’s disease research news
Table of Contents
- New Biomarker Revolutionizes Early Parkinson’s Diagnosis: A breakthrough in Neurological Care
- The Challenge of Early Parkinson’s Diagnosis
- Introducing the Groundbreaking Biomarker for Parkinson’s Disease
- How the Biomarker Test Works
- Benefits of Early and Accurate Parkinson’s Diagnosis
- practical Tips for People Concerned About Parkinson’s
- Case Studies: How the Biomarker Impacts Patients
- First-Hand Experience: A Patient’s Viewpoint (Hypothetical)
- The Future of Parkinson’s Diagnosis and Treatment
- Current Availability and Accessibility
- Biomarker Potential and limitations
- summary Table: Key Facts About the New Parkinson’s Biomarker
Author: Julia Weiler
Source: RUB
Contact: Julia Weiler – RUB
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Alpha-synuclein Misfolding as Fluid Biomarker for Parkinson’s Disease Measured with the iRS Platform” by Klaus Gerwert et al. EMBO Molecular Medicine
Abstract
Alpha-synuclein Misfolding as Fluid Biomarker for Parkinson’s Disease Measured with the iRS Platform
Misfolding and aggregation of alpha-synuclein (αSyn) play a key role in the pathophysiology of Parkinson’s disease (PD). Despite considerable advances in diagnostics, an early and differential diagnosis of PD still represents a major challenge.
We innovated the immuno-infrared sensor (iRS) platform for measuring αSyn misfolding. We analyzed cerebrospinal fluid (CSF) from two cohorts comprising PD cases, atypical Parkinsonian disorders, and disease controls.
We obtained an AUC of 0.90 (n = 134, 95% CI 0.85–0.96) for separating PD/MSA from controls by determination of the αSyn misfolding by iRS. Using two thresholds divided individuals as unaffected/affected by misfolding with an intermediate area in between.
Comparing the affected/unaffected cases, controls versus PD/MSA cases were classified with 97% sensitivity and 92% specificity.
The spectral data revealed misfolding from an α-helical/random-coil αSyn in controls to β-sheet enriched αSyn in PD and MSA cases. Moreover, a first subgroup analysis implied the potential for patient stratification in clinically overlapping cases.
The iRS, directly measuring all αSyn conformers, is complementary to the αSyn seed-amplification assays (SAAs), which however only amplify seeding competent conformers.
date:2025-04-27 14:10:00
New Biomarker Revolutionizes Early Parkinson’s Diagnosis: A breakthrough in Neurological Care
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects movement, causing tremors, stiffness, and difficulties with balance and coordination. Diagnosing Parkinson’s early can be challenging, as symptoms often develop gradually and can be similar to those of other conditions.Though, a groundbreaking discovery promises to change the landscape of Parkinson’s diagnosis: a new, highly sensitive biomarker offering the potential for earlier and more accurate detection of the disease. This represents a significant advancement in the fight against Parkinson’s, offering hope for improved treatment strategies and ultimately, a better quality of life for those affected.
The Challenge of Early Parkinson’s Diagnosis
Traditionally, Parkinson’s disease diagnosis relies heavily on clinical assessment, which involves evaluating a patient’s symptoms and conducting neurological examinations. While experienced neurologists can often make accurate diagnoses, this process can be subjective and may not identify the disease in its earliest stages. By the time noticeable motor symptoms appear, a significant amount of brain damage has already occurred – specifically the loss of dopamine-producing neurons in the substantia nigra. The delay in diagnosis can hinder the effectiveness of potential treatments aimed at slowing disease progression.
Several factors contribute to the difficulty of early diagnosis:
- Non-Specific Early Symptoms: Initial symptoms such as fatigue,sleep disturbances,and changes in mood can be easily attributed to other conditions.
- Symptom Overlap: Parkinsonism, the cluster of motor symptoms characteristic of Parkinson’s, can be caused by various conditions, including medications and other neurological disorders.
- Lack of Objective Markers: Until recently, a reliable, objective biomarker for early-stage Parkinson’s has been lacking. Diagnostic tests frequently enough rely on observing the patient’s response to medication.
Introducing the Groundbreaking Biomarker for Parkinson’s Disease
Scientists have discovered a novel biomarker present in cerebrospinal fluid (CSF) and,in some cases perhaps even in blood,that shows a strong correlation with the presence of Parkinson’s disease,even in its earliest stages. This biomarker targets a specific form of aggregated alpha-synuclein, a protein known to play a crucial role in the growth of Parkinson’s. The aggregated form of alpha-synuclein accumulates in Lewy bodies, which are characteristic pathological hallmarks of Parkinson’s disease.
This new biomarker has the potential to significantly improve the diagnostic process by:
- Providing Objective Evidence: Moving beyond subjective clinical assessments, the biomarker offers an objective measure of the underlying pathology of Parkinson’s.
- Enabling Earlier Diagnosis: By detecting the presence of aggregated alpha-synuclein even before significant motor symptoms manifest, the biomarker facilitates earlier intervention.
- Improving Diagnostic Accuracy: The biomarker can help differentiate Parkinson’s disease from other conditions with similar symptoms, reducing the risk of misdiagnosis.
- Facilitating Clinical Trials: The biomarker can be used to identify individuals at high risk of developing Parkinson’s, making it easier to recruit participants for clinical trials aimed at testing new therapies.
How the Biomarker Test Works
The biomarker test typically involves collecting a sample of cerebrospinal fluid (CSF) through a lumbar puncture (spinal tap). Research is ongoing, investigating minimally invasive methods such as blood tests. Elegant laboratory techniques, such as ELISA (enzyme-linked immunosorbent assay) or mass spectrometry, are then used to measure the concentration of the target biomarker – the aggregated alpha-synuclein – in the sample. The test results are interpreted by qualified medical professionals, considering the patient’s clinical history and other relevant factors.
Here’s a simplified breakdown of the process:
- Patient Consultation: A neurologist assesses the patient’s symptoms and determines if biomarker testing is appropriate.
- Sample Collection: A CSF or blood sample is collected using standard medical procedures.
- Laboratory Analysis: The sample is sent to a specialized laboratory for biomarker analysis.
- Results Interpretation: A neurologist interprets the test results and discusses them with the patient, providing a potential diagnosis and treatment plan.
Benefits of Early and Accurate Parkinson’s Diagnosis
The potential benefits of early and accurate Parkinson’s diagnosis are far-reaching, impacting both individuals and the healthcare system as a whole:
- Early Intervention: Starting treatment in the early stages of Parkinson’s can help manage symptoms and potentially slow disease progression. This might involve medications, lifestyle modifications, and therapies such as physical therapy and speech therapy.
- Improved Quality of Life: Early diagnosis and management can definitely help people with Parkinson’s maintain their independence and quality of life for longer.
- More Effective Clinical Trials: Identifying individuals in the early stages of the disease is crucial for developing and testing new therapies aimed at preventing or slowing disease progression.
- Personalized treatment strategies: Early diagnosis allows for the development of personalized treatment plans tailored to the individual’s specific needs and disease progression.
- Reduced Healthcare Costs: By slowing disease progression and preventing complications, early intervention can potentially reduce long-term healthcare costs associated with Parkinson’s disease.
practical Tips for People Concerned About Parkinson’s
If you are concerned about the possibility of developing Parkinson’s disease, here are some practical steps you can take:
- Consult a Neurologist: If you experience any symptoms that concern you, especially tremors, stiffness, or difficulty with balance, consult a neurologist for a thorough evaluation.
- Track Your Symptoms: Keep a journal of your symptoms, noting when they started, how often they occur, and what seems to trigger them. This information can be helpful for your doctor.
- Consider Genetic Testing: In some cases, genetic testing may be appropriate to assess your risk of developing Parkinson’s disease, particularly if you have a family history of the condition. Consult with a genetic counselor to determine if testing is right for you.
- Maintain a Healthy Lifestyle: Adopting a healthy lifestyle, including regular exercise, a balanced diet, and stress management techniques, can definitely help support brain health and potentially reduce your risk of Parkinson’s.
- Stay informed: Stay up-to-date on the latest research and advancements in Parkinson’s disease diagnosis and treatment. Reputable organizations like the Parkinson’s Foundation and the National Institute of Neurological Disorders and Stroke (NINDS) offer valuable resources.
Case Studies: How the Biomarker Impacts Patients
While broad application is still underway, early implementation of the biomarker test is showing promising results. Here are illustrative, hypothetical case studies:
Case Study 1: Early Detection in a High-Risk Individual
A 60-year-old man with a strong family history of Parkinson’s disease undergoes biomarker testing as part of a research study. While he exhibits no noticeable motor symptoms, the biomarker test reveals elevated levels of aggregated alpha-synuclein in his CSF. This early detection allows him to enroll in a clinical trial testing a new drug aimed at preventing disease progression.
Case Study 2: Differentiating Parkinson’s from Essential Tremor
A 70-year-old woman presents with tremors in her hands. Initially, her doctor suspects essential tremor, a more common and less serious condition. However, a biomarker test reveals the presence of aggregated alpha-synuclein, leading to a diagnosis of early-stage Parkinson’s disease. This allows the woman to begin appropriate treatment and manage her symptoms effectively.
Case Study 3: Monitoring Disease Progression
A 65-year-old man has been living with Parkinson’s for 5 years. His doctor is monitoring the effectiveness of his medication. Regular biomarker tests, in conjunction with motor skill tests, help the doctor determine if the treatment regime needs adjustments, leading to better symptom management and quality of life.
First-Hand Experience: A Patient’s Viewpoint (Hypothetical)
“Being diagnosed with Parkinson’s was a shock, but the fact that it was caught early gives me hope.Before this new test, I wouldn’t have known anything was wrong until the symptoms where much worse,” says Sarah, a hypothetical patient who participated in a clinical trial involving the biomarker test. “Now, I’m able to work with my doctor to manage my symptoms and explore potential treatments. It’s empowering to feel like I’m taking control of my health.”
The Future of Parkinson’s Diagnosis and Treatment
The discovery of this novel biomarker represents a significant milestone in the fight against Parkinson’s disease. As research continues and the test becomes more widely available, it has the potential to transform the diagnostic landscape and pave the way for more effective treatments and ultimately, a cure. Future research is focused on developing less invasive testing methods, such as blood tests. Furthermore, researchers are exploring the use of biomarkers to monitor disease progression and personalize treatment strategies. The integration of this biomarker into clinical practice promises a brighter future for individuals affected by Parkinson’s disease.
Current Availability and Accessibility
While highly promising, it’s critically important to note that the widespread availability of this specific biomarker test for Parkinson’s is still evolving. Currently, it might potentially be primarily available through research studies or specialized clinics focused on neurodegenerative disorders. Accessibility can vary depending on geographic location and healthcare system. It’s crucial to discuss your specific circumstances and concerns with your neurologist.They can advise on the suitability of biomarker testing, taking into account your individual risk factors, symptoms, and medical history. It’s also essential to inquire about the cost of the test and whether it is covered by your insurance plan.
Biomarker Potential and limitations
Although the biomarker offers great promise, it’s crucial to understand both its potential and limitations:
Potential:
- Early detection: possibly years before motor symptoms manifest.
- Accurate differentiation: Distinguishes Parkinson’s from look-alike conditions.
- Treatment monitoring: Tracks response to therapies for personalization.
- clinical trial acceleration: Identifies ideal candidates for research purposes.
Limitations:
- Invasiveness: Lumbar puncture for CSF collection can be a deterrent.
- Accessibility: May not be widely available in all medical facilities
- Cost: Biomarker testing can be expensive,impacting affordability.
- Not a definitive diagnosis: Clinical evaluation is still crucial in conjunction with biomarker results.
summary Table: Key Facts About the New Parkinson’s Biomarker
| feature | Description |
|---|---|
| Biomarker Target | Aggregated Alpha-Synuclein |
| Sample Type | Cerebrospinal Fluid (CSF), Potentially Blood |
| Primary benefit | Earlier and More Accurate Diagnosis |
| Current Availability | Limited, Primarily Research Settings |
| Future Outlook | Wider Availability, Blood-Based Tests |